Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aradigm's AERx inhaler "safe" for interferon:

This article was originally published in Clinica

Executive Summary

In what is claimed to be the first human trial of interferon-alpha 2b inhalation, Aradigm says its AERx pulmonary drug delivery device was "safe and well tolerated" in healthy volunteers. The advantage of pulmonary delivery over conventional subcutaneous injection of interferon-alpha 2b is that it could reduce the dosage needed to achieve a therapeutic effect. This in turn may reduce adverse events, such as flu-like symptoms, that are associated with injection, says the Hayward, California firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel